Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

• p. 9 Table 3 title

  Incidence of a First Episode of Severe Hypoglycemia.

• p. 9 Table 3 rows

  Any nonsevere symptomatic hypoglycemia

Only the authors can say what is right here.

Judge's note: Checked Table 3 on p.9. Two of its three sections cover nonsevere hypoglycemia, and the text (p.6) cites Table 3 for nonsevere rates and for participants without any symptomatic hypoglycemia. The title describes only the first section.

Second check: another model agreed

• p. 3 Results, Insulin Use and Achieved Fasting Glucose Levels

  After 1 year, 50% of the insulin-glargine group had a fasting plasma glucose level of 94 mg per deci-

• p. 6 Table 2, 1 yr row, insulin glargine FPG median

  93

• p. 3 Results, Insulin Use and Achieved Fasting Glucose Levels

  After 1 year, 50% of the insulin-glargine group had a fasting plasma glucose level of 94 mg per deciliter (5.2 mmol per liter) or less

• p. 3 Insulin use and achieved fasting glucose levels

  fasting plasma glucose level of 94 mg per deci-

Judge's note: Looked at the p.3 crop and Table 2 on p.6. The Table 2 glargine medians by year are 93, 90, 90, 91, 92, 94 and 94, so 94 is the largest median from year 1 to year 7. Read as a threshold that held at every visit ('94 or less ... maintained'), the sentence is true. It is still not the 1-yr median it seems to describe (93). Either wording could be intended, so this is a minor consistency point.

Second check: another model agreed

• p. 7 Discussion, first column

  participants in the standard-care group who used oral agents had a median fasting plasma glucose level of 123 mg per deciliter

• p. 4 Results, top of first column (continuing from p.3)

  level was 123 mg per deciliter (6.8 mmol per liter)

Only the authors can say what is right here.

Judge's note: Results (pp.3–4, text layer lines 271–284) give 123 mg/dl for the standard-care group as a whole at study end. The Discussion (p.7) gives the same figure for the subset using oral agents. No subgroup value is reported, so one of the two population descriptions does not match the number.

Second check: another model agreed

• p. 7 Discussion, first column

  values of less than 108 mg per deciliter (6.0 mmol per liter) were maintained in more than 75% of the group

• p. 6 Table 2, insulin glargine FPG IQR, 5–7 yr

  81–108

Only the authors can say what is right here.

Judge's note: Checked Table 2 on p.6. The glargine IQR upper bounds are 106, 104, 103, 105, 108, 110 and 113 for years 1–7. More than 75% below 108 holds for years 1–4 only. The sentence does not say which period it covers, while the preceding clause speaks of 'at least 5 years'. The text overstates the table.

Second check: another model agreed

• p. 7 Discussion, second paragraph

  11 more suspected or confirmed episodes per 100 person-years

• p. 9 Table 3, Any nonsevere symptomatic hypoglycemia

  3575 (16.72)

Judge's note: Checked Table 3 on p.9. The severe-hypoglycemia difference, 0.69, rounds to the printed 0.7, but the any-nonsevere difference, 11.56, rounds to 12, not 11. The Table 3 rates are also participants with at least 1 episode per 100 person-years, not episodes. The point is minor because the text says 'approximately'.

Second check: another model agreed

• p. 8 Discussion, limitations paragraph

  Finally, the ORIGIN trial was designed to test

• p. 8 Discussion, next paragraph

  Finally, no previously unrecognized adverse

Judge's note: Checked p.8. The limitations paragraph ends its list with 'Finally', and the next paragraph opens with 'Finally' as well. The second may be meant to close the whole discussion, but the repetition is a copy-editing slip.

Second check: none (judge only)

• p. 9 Disclosures, Dr. Ramachandran

  grant support through this institution from Merck Sharp &

Judge's note: Checked the p.9 disclosures. Every other entry says 'through his institution'; 'this' has no antecedent here, so it is a typo.

Second check: none (judge only)